{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:35:08Z","timestamp":1775158508646,"version":"3.50.1"},"reference-count":87,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Coronary artery disease is the leading cause of death in the US, and approximately 25% of MIs occurring each year are reinfarctions. Due to advances in percutaneous coronary intervention (PCI) and medical therapy, patients with prior MIs live longer but may be susceptible to additional cardiac events. Thus, secondary prevention after MI or PCI is key to improving mortality and quality of life. This review discusses pharmacotherapies and lifestyle interventions with a special focus on cardiac rehabilitation in the post-MI or PCI period to improve cardiovascular outcomes.<\/jats:p>","DOI":"10.15420\/usc.2024.34","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:54:34Z","timestamp":1736765674000},"source":"Crossref","is-referenced-by-count":5,"title":["Pharmacotherapy, Lifestyle Modification, and Cardiac Rehabilitation after Myocardial Infarction or Percutaneous Intervention"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3218-329X","authenticated-orcid":false,"given":"Nicholas","family":"Nguyen","sequence":"first","affiliation":[{"name":"Methodist Dallas Medical Center, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0371-5533","authenticated-orcid":false,"given":"Katherine C","family":"Michelis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dallas VA Medical Center, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"ref0","unstructured":"Centers for Disease Control and Prevention. Heart Disease Facts. 2023. https:\/\/www.cdc.gov\/heart-disease\/data-research\/facts-stats\/ (accessed\u00a0February 5, 2024)."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. Deaths from coronary disease, 1980\u20132000. N Engl J Med 2007;356:2388\u201398. https:\/\/doi.org\/10.1056\/NEJMsa053935; PMID:\u00a017554120.","DOI":"10.1056\/nejmsa053935"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Peters SAE, Colantonio LD, Dai Y, et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation 2021;143:650\u201360. https:\/\/doi.org\/10.1161\/circulationaha.120.047065; PMID:\u00a032951451.","DOI":"10.1161\/circulationaha.120.047065"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual antiplatelet therapy in coronary artery disease. Cardiol Ther 2020;9:349\u201361. https:\/\/doi.org\/10.1007\/s40119-020-00197-0; PMID:\u00a032804330.","DOI":"10.1007\/s40119-020-00197-0"},{"key":"ref4","unstructured":"Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;29:e21\u2212129. https:\/\/doi.org\/10.1016\/j.jacc.2021.09.006; PMID:\u00a034895950."},{"key":"ref5","unstructured":"Writing Committee Members, Virani SS, Newby LK, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease. J Am Coll Cardiol;82:833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003; PMID:\u00a037480922."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Khan SU, Singh M, Valavoor S, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation 2020;142:1425\u201336. https:\/\/doi.org\/10.1161\/circulationaha.120.046308; PMID:\u00a032795096.","DOI":"10.1161\/circulationaha.120.046308"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Knijnik L, Fernandes M, Rivera M, et al. Meta-analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting. Am J Cardiol 2021;151:25\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2021.04.014; PMID:\u00a034049672.","DOI":"10.1016\/j.amjcard.2021.04.014"},{"key":"ref8","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78\u2013e140. https:\/\/doi.org\/10.1016\/j.jacc.2012.11.019; PMID:\u00a023256914."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Freemantle N, Cleland J, Young P, et al. \u03b2 blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730\u20137. https:\/\/doi.org\/10.1136\/bmj.318.7200.1730; PMID:\u00a010381708.","DOI":"10.1136\/bmj.318.7200.1730"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024;390:1372\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2401479; PMID:\u00a038587241.","DOI":"10.1056\/NEJMoa2401479"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Ishak D, Aktaa S, Lindhagen L, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart 2023;109:1159\u201365. https:\/\/doi.org\/10.1136\/heartjnl-2022-322115; PMID:\u00a037130746.","DOI":"10.1136\/heartjnl-2022-322115"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation 2019;139:e1082\u2212143. https:\/\/doi.org\/10.1161\/cir.0000000000000625; PMID:\u00a030586774","DOI":"10.1161\/CIR.0000000000000698"},{"key":"ref13","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144; PMID:\u00a028444290."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1; PMID:\u00a016214597.","DOI":"10.1016\/s0140-6736(05)67394-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5; PMID:\u00a021067804.","DOI":"10.1016\/s0140-6736(10)61350-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489; PMID:\u00a026039521.","DOI":"10.1056\/nejmoa1410489"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Kyt\u00f6 V, Tornio A. Ezetimibe use and mortality after myocardial infarction: a nationwide cohort study. Am J Prev Cardiol 2024;19:100702. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100702; PMID:\u00a039070026.","DOI":"10.1016\/j.ajpc.2024.100702"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174; PMID:\u00a030403574.","DOI":"10.1056\/NEJMoa1801174"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664; PMID:\u00a028304224.","DOI":"10.1056\/nejmoa1615664"},{"key":"ref20","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024; PMID:\u00a036876740."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3; PMID:\u00a017398308.","DOI":"10.1016\/s0140-6736(07)60527-3"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792; PMID:\u00a030415628.","DOI":"10.1056\/nejmoa1812792"},{"key":"ref23","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191; PMID:\u00a037622654."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Gruppoitalianoperlostudiodell. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(94)90232-1.","DOI":"10.1016\/s0140-6736(94)90232-1"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Miocardico N. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks atter acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996;27:337\u201344. https:\/\/doi.org\/10.1016\/0735-1097(95)00498-X; PMID:\u00a08557903.","DOI":"10.1016\/0735-1097(95)00498-x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669\u201377. https:\/\/doi.org\/10.1056\/nejm199209033271001; PMID:\u00a01386652.","DOI":"10.1056\/nejm199209033271001"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670\u20136. https:\/\/doi.org\/10.1056\/nejm199512213332503; PMID:\u00a07477219.","DOI":"10.1056\/nejm199512213332503"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Packer M, Desai AS, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077; PMID:\u00a025176015.","DOI":"10.1056\/nejmoa1409077"},{"key":"ref29","unstructured":"Montalescot G, Pitt B, Lopez de Sa E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J 2014;35:2295\u2013302. https:\/\/doi.org\/10.1093\/eurheartj\/ehu164; PMID:\u00a024780614."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720; PMID:\u00a026378978.","DOI":"10.1056\/nejmoa1504720"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x; PMID:\u00a030424892.","DOI":"10.1016\/s0140-6736(18)32590-x"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744; PMID:\u00a030990260.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5; PMID:\u00a034425083.","DOI":"10.1016\/s2213-8587(21)00203-5"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID:\u00a037952131.","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref35","unstructured":"U.S. Department of Health and Human Services. Smoking Cessation: a report of the Surgeon General. 2020. https:\/\/www.hhs.gov\/sites\/default\/files\/2020-cessation-sgr-full-report.pdf (accessed February 5, 2024)."},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Gerber Y, Rosen LJ, Goldbourt U, et al. Smoking status and long-term survival after first acute myocardial infarction: a population-based cohort study. J Am Coll Cardiol 2009;54:2382\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.09.020; PMID:\u00a020082928.","DOI":"10.1016\/j.jacc.2009.09.020"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2016;3:CD008286. https:\/\/doi.org\/10.1002\/14651858.CD008286.pub3; PMID:\u00a027009521.","DOI":"10.1002\/14651858.cd008286.pub3"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Suissa K, Larivi\u00e8re J, Eisenberg MJ, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458. https:\/\/doi.org\/10.1161\/circoutcomes.115.002458; PMID:\u00a028093398.","DOI":"10.1161\/circoutcomes.115.002458"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015;3:761\u20138. https:\/\/doi.org\/10.1016\/S2213-2600(15)00320-3; PMID:\u00a026355008.","DOI":"10.1016\/s2213-2600(15)00320-3"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)30272-0; PMID:\u00a027116918.","DOI":"10.1016\/s0140-6736(16)30272-0"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med 2018;178:622\u201331. https:\/\/doi.org\/10.1001\/jamainternmed.2018.0397; PMID:\u00a029630702.","DOI":"10.1001\/jamainternmed.2018.0397"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Windle SB, Dehghani P, Roy N, et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 2018;190:E347\u201354. https:\/\/doi.org\/10.1503\/cmaj.170377; PMID:\u00a029581161.","DOI":"10.1503\/cmaj.170377"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Lovatt S, Wong CW, Holroyd E, et al. Smoking cessation after acute coronary syndrome: a systematic review and meta-analysis. Int J Clin Pract 2021;75:e14894. https:\/\/doi.org\/10.1111\/ijcp.14894; PMID:\u00a034541754.","DOI":"10.1111\/ijcp.14894"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30\u20138. https:\/\/doi.org\/10.1111\/j.1525-1497.2005.00269.x; PMID:\u00a016423120.","DOI":"10.1111\/j.1525-1497.2005.00269.x"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Frasure-Smith N, Lesp\u00e9rance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819\u201325. https:\/\/doi.org\/10.1001\/jama.1993.03510150053029; PMID:\u00a08411525.","DOI":"10.1001\/jama.1993.03510150053029"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Meijer A, Conradi HJ, Bos EH, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry 2011;33:203\u201316. https:\/\/doi.org\/10.1016\/j.genhosppsych.2011.02.007; PMID:\u00a021601716.","DOI":"10.1016\/j.genhosppsych.2011.02.007"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease: cochrane systematic review and meta-analysis. Eur J Prev Cardiol 2018;25:247\u201359. https:\/\/doi.org\/10.1177\/2047487317739978; PMID:\u00a029212370.","DOI":"10.1177\/2047487317739978"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA 2003;289:3106\u201316. https:\/\/doi.org\/10.1001\/jama.289.23.3106; PMID:\u00a012813116.","DOI":"10.1001\/jama.289.23.3106"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792\u20138. https:\/\/doi.org\/10.1001\/archpsyc.62.7.792; PMID:\u00a015997021.","DOI":"10.1001\/archpsyc.62.7.792"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kim JM, Bae KY, Stewart R, et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. J Clin Psychiatry 2015;76:62\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09281; PMID:\u00a025375836.","DOI":"10.4088\/jcp.14m09281"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kim JM, Stewart R, Lee YS, et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA 2018;320:350\u20138. https:\/\/doi.org\/10.1001\/jama.2018.9422; PMID:\u00a030043065.","DOI":"10.1001\/jama.2018.9422"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Li YN, Buys N, Ferguson S, et al. Effectiveness of cognitive behavioral therapy-based interventions on health outcomes in patients with coronary heart disease: a meta-analysis. World J Psychiatry 2021;11:1147\u201366. https:\/\/doi.org\/10.5498\/wjp.v11.i11.1147; PMID:\u00a034888180.","DOI":"10.5498\/wjp.v11.i11.1147"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehy913; PMID:\u00a030698764.","DOI":"10.1093\/eurheartj\/ehy913"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(04)17018-9; PMID:\u00a015364185.","DOI":"10.1016\/s0140-6736(04)17018-9"},{"key":"ref55","unstructured":"Miller V, Mente A, Dehghan M, et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet 2017;390:2037\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(17)32253-5; PMID:\u00a028864331."},{"key":"ref56","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice guidelines. J Am Coll Cardiol 2019;74:e177\u2013232. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010; PMID:\u00a030894318."},{"key":"ref57","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227\u2212337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484; PMID:\u00a034458905."},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Belardo D, Michos ED, Blankstein R, et al. Practical, evidence-based approaches to nutritional modifications to reduce atherosclerotic cardiovascular disease: an American society for preventive cardiology clinical practice statement. Am J Prev Cardiol 2022;10:100323. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100323; PMID:\u00a035284849.","DOI":"10.1016\/j.ajpc.2022.100323"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779\u201385. https:\/\/doi.org\/10.1161\/01.cir.99.6.779; PMID:\u00a09989963.","DOI":"10.1161\/01.cir.99.6.779"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Henzel J, K\u0119pka C, Kruk M, et al. High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study. JACC Cardiovasc Imaging 2021;14:1192\u2013202. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.019; PMID:\u00a033341413.","DOI":"10.1016\/j.jcmg.2020.10.019"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Jabri A, Kumar A, Verghese E, et al. Meta-analysis of effect of vegetarian diet on ischemic heart disease and all-cause mortality. Am J Prev Cardiol 2021;7:100182. https:\/\/doi.org\/10.1016\/j.ajpc.2021.100182; PMID:\u00a034611632.","DOI":"10.1016\/j.ajpc.2021.100182"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and unhealthful plant-based diets and the risk of coronary heart disease in U.S. adults. J Am Coll Cardiol 2017;70:411\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.047; PMID:\u00a028728684.","DOI":"10.1016\/j.jacc.2017.05.047"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Wheless JW. History of the ketogenic diet. Epilepsia 2008;49(Suppl 8):3\u20135. https:\/\/doi.org\/10.1111\/j.1528-\u200b1167.2008.01821.x; PMID:\u00a019049574.","DOI":"10.1111\/j.1528-1167.2008.01821.x"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Li S, Flint A, Pai JK, et al. Low carbohydrate diet from plant or animal sources and mortality among myocardial infarction survivors. J Am Heart Assoc 2014;3:e001169. https:\/\/doi.org\/10.1161\/jaha.114.001169; PMID:\u00a025246449.","DOI":"10.1161\/jaha.114.001169"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992;12:911\u20139. https:\/\/doi.org\/10.1161\/01.atv.12.8.911; PMID:\u00a01386252.","DOI":"10.1161\/01.atv.12.8.911"},{"key":"ref66","unstructured":"Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117\u201324. https:\/\/doi.org\/10.1056\/nejm199704173361601; PMID:\u00a09099655."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3\u201310. https:\/\/doi.org\/10.1056\/nejm200101043440101; PMID:\u00a011136953.","DOI":"10.1056\/nejm200101043440101"},{"key":"ref68","unstructured":"Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(18)30134-x; PMID:\u00a029676281."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Pallazola VA, Davis DM, Whelton SP, et al. A clinician\u2019s guide to healthy eating for cardiovascular disease prevention. Mayo Clin Proc Innov Qual Outcomes 2019;3:251\u201367. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2019.05.001; PMID:\u00a031485563.","DOI":"10.1016\/j.mayocpiqo.2019.05.001"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Ekblom O, Ek A, Cider \u00c5, et al. Increased physical activity post\u2013myocardial infarction is related to reduced mortality: results from the SWEDEHEART registry. J Am Heart Assoc 2018;7:e010108. https:\/\/doi.org\/10.1161\/jaha.118.010108; PMID:\u00a030561263.","DOI":"10.1161\/jaha.118.010108"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Van Veldhuisen SL, Gorter TM, Van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2022;43:1955\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehac071; PMID:\u00a035243488.","DOI":"10.1093\/eurheartj\/ehac071"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ 2015;351:h5000. https:\/\/doi.org\/10.1136\/bmj.h5000; PMID:\u00a026419744.","DOI":"10.1136\/bmj.h5000"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005;111:369\u201376. https:\/\/doi.org\/10.1161\/01.cir.0000151788.08740.5c; PMID:\u00a015668354.","DOI":"10.1161\/01.cir.0000151788.08740.5c"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Menezes AR, Lavie CJ, Milani RV, et al. Cardiac rehabilitation in the United States. Prog Cardiovasc Dis 2014;56:522\u20139. https:\/\/doi.org\/10.1016\/j.pcad.2013.09.018; PMID:\u00a024607017.","DOI":"10.1016\/j.pcad.2013.09.018"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988;260:945\u201350. https:\/\/doi.org\/10.1001\/jama.1988.03410070073031; PMID:\u00a03398199.","DOI":"10.1001\/jama.1988.03410070073031"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"O\u2019Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234\u201344. https:\/\/doi.org\/10.1161\/01.cir.80.2.234; PMID:\u00a02665973.","DOI":"10.1161\/01.cir.80.2.234"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009;54:25\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2009.01.078; PMID:\u00a019555836.","DOI":"10.1016\/j.jacc.2009.01.078"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Dibben GO, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J 2023;44:452\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehac747; PMID:\u00a036746187.","DOI":"10.1093\/eurheartj\/ehac747"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation 2010;121:63\u201370. https:\/\/doi.org\/10.1161\/circulationaha.109.876383; PMID:\u00a020026778.","DOI":"10.1161\/circulationaha.109.876383"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007;120:799\u2013806. https:\/\/doi.org\/10.1016\/j.amjmed.2007.03.026; PMID:\u00a017765050.","DOI":"10.1016\/j.amjmed.2007.03.026"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Van Camp SP, Peterson RA. Cardiovascular complications of outpatient cardiac rehabilitation programs. JAMA 1986;256:1160\u20133. https:\/\/doi.org\/10.1001\/jama.256.9.1160; PMID:\u00a03735650.","DOI":"10.1001\/jama.256.9.1160"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Pavy B, Iliou MC, Meurin P, et al. Safety of exercise training for cardiac patients: results of the French registry of complications during cardiac rehabilitation. Arch Intern Med 2006;166:2329\u201334. https:\/\/doi.org\/10.1001\/archinte.166.21.2329; PMID:\u00a017130385.","DOI":"10.1001\/archinte.166.21.2329"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Colella TJF, Gravely S, Marzolini S, et al. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta-analysis. Eur J Prev Cardiol 2015;22:423\u201341. https:\/\/doi.org\/10.1177\/2047487314520783; PMID:\u00a024474091.","DOI":"10.1177\/2047487314520783"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Wang L, Liu J, Fang H, Wang X. Factors associated with participation in cardiac rehabilitation in patients with acute myocardial infarction: a systematic review and meta-analysis. Clin Cardiol 2023;46:1450\u20137. https:\/\/doi.org\/10.1002\/clc.24130; PMID:\u00a037594292.","DOI":"10.1002\/clc.24130"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Schopfer DW, Whooley MA, Allsup K, et al. Effects of home-based cardiac rehabilitation on time to enrollment and functional status in patients with ischemic heart disease. J Am Heart Assoc 2020;9:e016456. https:\/\/doi.org\/10.1161\/jaha.120.016456; PMID:\u00a032954885.","DOI":"10.1161\/jaha.120.016456"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Seron P, Oliveros MJ, Marzuca-Nassr GN, et al. Hybrid cardiac rehabilitation program in a low-resource setting: a randomized clinical trial. JAMA Netw Open 2024;7:e2350301. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50301; PMID:\u00a038194236.","DOI":"10.1001\/jamanetworkopen.2023.50301"}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:54:54Z","timestamp":1736765694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":87,"URL":"https:\/\/doi.org\/10.15420\/usc.2024.34","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"value":"1758-390X","type":"electronic"},{"value":"1758-3896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"e01"}}